Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
The European pharmaceutical industry uses the alleged efficacy of self-regulation to question the need for transparency laws similar to the US Physici…
Mulinari, S., Martinon, L., Jachiet, P. A., & Ozieranski, P. (2021).
Health Policy, 125(7), 915-922.
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
Objectives To examine the accessibility and quality of drug company payment data in Europe. Design Comparative policy review of payment data in countries with different regulatory approaches to disclosure. Setting 37 European countries. Participants European Federation of Pharmaceutical Industrie…
Ozieranski, P., Martinon, L., Jachiet, P. A., & Mulinari, S. (2021).
Tip of The Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
Background Creating new therapies often involves drug companies paying healthcare professionals and institutions for research and development (R&D) activities, including clinical trials. However, industry sponsorship can create conflicts of interests. We analysed approaches to drug company R&D paym…
Ozieranski, P., Martinon, L., Jachiet, P. A., & Mulinari, S. (2022).
International Journal of Health Policy and Management.